Compare AbbVie Inc (ABBV) vs Fox Corp Class A (FOXA) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

FOXA trades at $55.87, down 1.08% with bearish technical signals despite strong fundamentals. The company reported robust earnings with Q1 2026 EPS of $1.32 beating expectations by 29%, continuing a trend of quarterly beats. Revenue grew to $16.3B in 2025 with net income margin expanding to 13.88%. However, the stock faces headwinds from the recent $22B Roku acquisition announcement, which has raised leverage concerns and contributed to recent price weakness.

The outlook remains balanced with 50% analyst buy ratings and a $67.80 consensus target suggesting 21% upside potential. Key risks include integration challenges from the Roku acquisition and streaming competition, while opportunities lie in advertising growth from World Cup events and Tubi streaming momentum. Valuation appears reasonable with P/E of 14.7x and EV/EBITDA of 8.4x.